<DOC>
	<DOC>NCT01069627</DOC>
	<brief_summary>This study will investigate the efficacy and safety of bevacizumab + fotemustine in patients with stage IV melanoma, previously untreated with chemo- or immunotherapy for metastatic disease. Patients will receive Avastin (15mg/kg intravenously[IV]) on Day 1 of every 3 week cycle, in combination with fotemustine (100mg/m² IV) on Days 1, 8 and 15, followed by 4 weeks rest, followed by 100mg/m² IV every 3 weeks for 4-6 cycles. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<criteria>cutaneous malignant melanoma; advanced, inoperable stage IV melanoma; measurable and/or evaluable sites of metastases. prior chemotherapy and/or IFN/IL2 based immunotherapy for metastatic disease; prior malignancies within past 5 years, with the exception of cured nonmelanoma skin cancer, or in situ cancer of cervix; clinically significant cardiovascular disease; ongoing treatment with aspirin (&gt;325mg/day) or other medications known to predispose to gastrointestinal ulceration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>